Testing of tozasertib, a pan aurora kinase inhibitor [16], and alisertib, a second generation aurora kinase inhibitor that inhibits aurora kinase A and B with a higher affinity to aurora kinase A [17], in a panel of drug-resistant neuroblastoma cell lines revealed differing activity profiles. Here, AURKA is linked to neuroblastoma.